Latest Oramed Pharmaceuticl (ORMP) Headlines Na
Post# of 54
Posted On: 03/13/2014 12:09:39 PM
Latest Oramed Pharmaceuticl (ORMP) Headlines
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
AutoCanada Inc. Announces its Twelfth Consecutive Quarterly Dividend Increase
PR Newswire - Fri Feb 14, 11:30AM CST
AutoCanada Inc. ("AutoCanada") (TSX:ACQ) today announced that its Board of Directors has declared a quarterly eligible dividend of $0.22 per common share, an increase of 4.8% from the previous quarterly dividend of $0.21 per common share. The dividend is payable on March 17, 2014 to shareholders of record at the close of business on February 28, 2014. The declared dividend represents a rate of $0.88 per share on an annualized basis.
Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule
PR Newswire - Mon Feb 10, 8:47AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oramed Pharmaceuticals, Inc.
PR Newswire - Tue Feb 04, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (NasdaqCM: ORMP). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oramed Pharmaceuticals Inc. - ORMP
PR Newswire - Mon Feb 03, 11:51AM CST
Pomerantz LLP is investigating claims on behalf of investors of Oramed Pharmaceuticals, Inc. ("Oramed" or the "Company") (NasdaqGS: ORMP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Oramed's Oral Insulin Pill Data 'Completely Worthless'
at The Street - Mon Feb 03, 8:34AM CST
Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oramed Announces Successful FDA Phase 2a Clinical Trial Results
PR Newswire - Thu Jan 30, 3:00AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Oramed Pharmaceuticals: Monday’s Top Stock
David Williamson, The Motley Fool - Motley Fool - Mon Jan 27, 7:47PM CST
Even though the markets took a beating over the past week and biotech stocks experienced a broader industry sell-off, one stock in this space stood out as the clear winner on the market on Monday. Shares of Oramed Pharmaceuticals were up more than...
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 12, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Oramed Granted its 3rd Patent in Australia for Oral Administration of Exenatide
PR Newswire - Tue Mar 11, 7:30AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government's patent office, has issued the Company its third patent in the country. The patent, titled "Methods and Compositions for Oral Administration of Exenatide," covers oral exenatide compositions made using the company's proprietary technology, including its ORMD-0901 oral exenatide capsule.
Oramed to Present at Upcoming Conferences
PR Newswire - Thu Mar 06, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company will present at the following conferences in March 2014:
Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014
PR Newswire - Mon Mar 03, 7:20AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
PeopleLinx Achieves 300% Sales Growth in 2013 and Signs Over 40 Top Brands
PR Newswire - Tue Feb 18, 8:03AM CST
PeopleLinx, provider of automated marketing and training solutions for LinkedIn, announced today that the company achieved 300% sales growth in 2013 and signed over 40 new brands. As brands create new sales, marketing and recruitment opportunities through LinkedIn, PeopleLinx has met demand for software that can manage employee training, content sharing and analytics at enterprise scale.
AutoCanada Inc. Announces its Twelfth Consecutive Quarterly Dividend Increase
PR Newswire - Fri Feb 14, 11:30AM CST
AutoCanada Inc. ("AutoCanada") (TSX:ACQ) today announced that its Board of Directors has declared a quarterly eligible dividend of $0.22 per common share, an increase of 4.8% from the previous quarterly dividend of $0.21 per common share. The dividend is payable on March 17, 2014 to shareholders of record at the close of business on February 28, 2014. The declared dividend represents a rate of $0.88 per share on an annualized basis.
Oramed Submits Phase 2a Protocol to FDA for the Treatment of Type 1 Diabetes with its Oral Insulin Capsule
PR Newswire - Mon Feb 10, 8:47AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted a protocol to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Oramed Pharmaceuticals, Inc.
PR Newswire - Tue Feb 04, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (NasdaqCM: ORMP). Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oramed Pharmaceuticals Inc. - ORMP
PR Newswire - Mon Feb 03, 11:51AM CST
Pomerantz LLP is investigating claims on behalf of investors of Oramed Pharmaceuticals, Inc. ("Oramed" or the "Company") (NasdaqGS: ORMP). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Oramed's Oral Insulin Pill Data 'Completely Worthless'
at The Street - Mon Feb 03, 8:34AM CST
Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Oramed Announces Successful FDA Phase 2a Clinical Trial Results
PR Newswire - Thu Jan 30, 3:00AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, announced today results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes. The trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol. The Phase 2a study met all primary and secondary endpoints.
Oramed Pharmaceuticals: Monday’s Top Stock
David Williamson, The Motley Fool - Motley Fool - Mon Jan 27, 7:47PM CST
Even though the markets took a beating over the past week and biotech stocks experienced a broader industry sell-off, one stock in this space stood out as the clear winner on the market on Monday. Shares of Oramed Pharmaceuticals were up more than...
(0)
(0)Oramed Pharmaceuticals Inc. (ORMP) Stock Research Links
Scroll down for more posts ▼